Iaso Therapeutics, Inc.


Iaso has developed a novel self-assembled mutant Qβ (mQβ) bacteriophage capsid protein. The mQβ platform is an exciting new carrier for conjugate vaccines, providing an attractive alternative to current carriers. Also, mQβ carriers are associated with reduced antibody generation against the carrier while retaining the ability to elicit high levels of anti-antigen IgG antibodies compared to wild type Qβ. In head-to-head comparison studies, mQβ can induce a 3-10-fold higher IgG antibody titer when compared to CRM‑197 or keyhole limpet hemocyanin (KLH), respectively. Both are benchmark carrier proteins commonly utilized as a carrier moieties in vaccine studies. The mQβ carriers are a platform technology suitable for developing various vaccines.
Non-ToxicThe carrier itself does not need to be altered to be non-toxicEase of manufacturing
Ease of manufacturingSimple bacterial fermentation No expensive purifications
Uniformity of CarrierEase of manufacturingHigher yield in fermentation because you do not have to purify away from related products.
Ab Titer GeneratedHigher antibody titers compared to other carrier proteinsDo not need to have booster injections as often
Ability to generate mutantsOptimize antigen presentation to the immune systemHigher IgG production
Self-AdjuvantNot necessary to add adjuvantHigher IgG production
Persistent Antigen-specific Ab titersNot necessary to boost injection as oftenFewer injections
Low Ab production to carrier
It can be stored at R.T. as a lyophilized powderVery stable productNo need to store it in Freezer